3 Things In Biotech, April 1: Fate's Omens, Mallinckrodt's Trial, Insmed's Journey


Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. News: FATE announced the presentation of early findings from its phase 1 APOLLO study investigating its natural killer-based immunotherapy FATE-NK100 in patients with recurrent ovarian cancer.



from Biotech News